Ionis Pharmaceuticals (IONS) to Present Phase 2 Results of donidalorsen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Ionis Pharmaceuticals (IONS) PT Lowered to $38 at Stifel, Following Earnings
November 4, 2021 11:45 AM EDTStifel analyst Paul Matteis lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $38.00 (from $42.00) while maintaining a Hold rating.
Analyst comments: "The stock continues to face headwinds after multiple set-backs including the recent miss in the ph3 study of BIIB-partnered... More
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Needham & Company
November 4, 2021 7:28 AM EDTNeedham & Company analyst Chad Messer lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $84.00) while maintaining a Buy rating.
The analyst commented, "IONS reported 3Q21 financial results yesterday, and we spoke w/ mgmt for additional details. Partner BIIB (not rated) previously... More
Ionis Pharmaceuticals (IONS) PT Lowered to $33 at Barclays
November 4, 2021 4:56 AM EDTBarclays analyst Gena Wang lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $33.00 (from $38.00) while maintaining a Equalweight rating.... More
